1 Broadway # 14, Cambridge, MA 02142
The first indication for SDX-7320 is in post-menopausal HR+, Her2- metastatic breast cancer with the PIK3CA mutation in combination with standard of care treatment. We are currently planning on starting this Phase 1b/2 combination study in mid-2020.
Clinical trials for other indications (e.g. metastatic colorectal, hepatacellular carcinoma (liver cancer), NSCLC) will follow later in 2020.